BRPI0821114B8 - Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto - Google Patents

Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Info

Publication number
BRPI0821114B8
BRPI0821114B8 BRPI0821114A BRPI0821114A BRPI0821114B8 BR PI0821114 B8 BRPI0821114 B8 BR PI0821114B8 BR PI0821114 A BRPI0821114 A BR PI0821114A BR PI0821114 A BRPI0821114 A BR PI0821114A BR PI0821114 B8 BRPI0821114 B8 BR PI0821114B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
antitumor
preparing
antitumor compound
Prior art date
Application number
BRPI0821114A
Other languages
English (en)
Inventor
Rodríguez Vicente Alberto
Murcia Pérez Carmen
Mateo Urbano Cristina
Sánchez Sancho Francisco
Digón Juárez Isabel
del Carmen Cuevas Marchante María
Garranzo García-Ibarrola María
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BRPI0821114A2 publication Critical patent/BRPI0821114A2/pt
Publication of BRPI0821114B1 publication Critical patent/BRPI0821114B1/pt
Publication of BRPI0821114B8 publication Critical patent/BRPI0821114B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto. um composto de fórmula geral i: em que r11, r12, r13, r14, r15, w, y, r1, r2, r3, r4, r5, e r6 têm vários significados para o uso no tratamento de câncer.
BRPI0821114A 2007-12-20 2008-12-19 Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto BRPI0821114B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
EP07123882.8 2007-12-20
PCT/EP2008/068065 WO2009080769A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (3)

Publication Number Publication Date
BRPI0821114A2 BRPI0821114A2 (pt) 2015-06-16
BRPI0821114B1 BRPI0821114B1 (pt) 2021-09-08
BRPI0821114B8 true BRPI0821114B8 (pt) 2021-11-09

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0821116A BRPI0821116B8 (pt) 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BRPI0821114A BRPI0821114B8 (pt) 2007-12-20 2008-12-19 Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0821116A BRPI0821116B8 (pt) 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo

Country Status (26)

Country Link
US (4) US8710264B2 (pt)
EP (3) EP2231633B1 (pt)
JP (3) JP5529038B2 (pt)
KR (3) KR101639772B1 (pt)
CN (4) CN102190643B (pt)
AT (1) ATE549313T1 (pt)
AU (2) AU2008341671B2 (pt)
BR (2) BRPI0821116B8 (pt)
CA (2) CA2715203C (pt)
CY (1) CY1117245T1 (pt)
DK (2) DK2231590T3 (pt)
ES (3) ES2384420T3 (pt)
HR (2) HRP20140015T1 (pt)
IL (3) IL206396A (pt)
MX (2) MX2010006795A (pt)
MY (3) MY148651A (pt)
NZ (3) NZ597526A (pt)
PL (2) PL2231590T3 (pt)
PT (2) PT2231590E (pt)
RS (2) RS53140B (pt)
RU (3) RU2493147C2 (pt)
SG (2) SG170778A1 (pt)
SI (2) SI2231590T1 (pt)
UA (3) UA106967C2 (pt)
WO (2) WO2009080769A1 (pt)
ZA (3) ZA201004017B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
WO2013103155A1 (en) * 2012-01-05 2013-07-11 Kao Corporation Agent for reduction of sensory irritation
MA38588B1 (fr) 2013-04-16 2018-04-30 Idorsia Pharmaceuticals Ltd Dérivés bi-aromatiques antibactériens
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
US6528510B1 (en) 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
AU2004263287B2 (en) * 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
EP2404912A3 (en) 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi

Also Published As

Publication number Publication date
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
BRPI0821114B1 (pt) 2021-09-08
JP2014133752A (ja) 2014-07-24
EP2231590B1 (en) 2012-03-14
HK1147990A1 (en) 2011-08-26
MY155342A (en) 2015-10-15
RU2493147C2 (ru) 2013-09-20
IL206397A (en) 2014-01-30
JP5529038B2 (ja) 2014-06-25
JP5860088B2 (ja) 2016-02-16
CN101903367A (zh) 2010-12-01
IL206396A (en) 2014-05-28
CN102174058A (zh) 2011-09-07
US9187445B2 (en) 2015-11-17
HK1180678A1 (en) 2013-10-25
IL206396A0 (en) 2010-12-30
US20120041063A2 (en) 2012-02-16
EP2231633B1 (en) 2013-10-30
JP5727228B2 (ja) 2015-06-03
IL206397A0 (en) 2010-12-30
MX2010006796A (es) 2010-10-26
UA106967C2 (uk) 2014-11-10
MY164533A (en) 2017-12-29
RU2013112003A (ru) 2014-08-20
DK2231590T3 (da) 2012-07-09
US20150344454A1 (en) 2015-12-03
ES2442140T3 (es) 2014-02-25
JP2011506575A (ja) 2011-03-03
CN102190643A (zh) 2011-09-21
PL2231633T3 (pl) 2014-03-31
SI2231590T1 (sl) 2012-10-30
RU2528393C9 (ru) 2015-01-10
EP2231633A1 (en) 2010-09-29
EP2597091A1 (en) 2013-05-29
IL229594A (en) 2016-02-29
AU2008341670B2 (en) 2012-04-19
PT2231590E (pt) 2012-06-25
UA104281C2 (ru) 2014-01-27
RU2528393C1 (ru) 2014-09-20
ZA201106371B (en) 2013-05-29
CN101903367B (zh) 2015-08-05
BRPI0821116B1 (pt) 2020-02-18
JP2011506578A (ja) 2011-03-03
CN101903337A (zh) 2010-12-01
HK1147998A1 (en) 2011-08-26
RS52343B (sr) 2012-12-31
SI2231633T1 (sl) 2014-02-28
ES2384420T3 (es) 2012-07-04
AU2008341671B2 (en) 2012-07-26
KR20150076265A (ko) 2015-07-06
SG170779A1 (en) 2011-05-30
HRP20120464T1 (hr) 2012-07-31
ZA201004018B (en) 2011-12-28
US9827257B2 (en) 2017-11-28
CA2710087A1 (en) 2009-07-02
BRPI0821116A2 (pt) 2015-08-11
MX2010006795A (es) 2010-10-26
AU2008341670A1 (en) 2009-07-02
CN101903337B (zh) 2013-12-18
KR101541436B1 (ko) 2015-08-03
IL229594A0 (en) 2014-01-30
US8710264B2 (en) 2014-04-29
RS53140B (sr) 2014-06-30
CN102190643B (zh) 2015-02-25
RU2010130180A (ru) 2012-01-27
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
WO2009080761A1 (en) 2009-07-02
BRPI0821116B8 (pt) 2021-05-25
SG170778A1 (en) 2011-05-30
CA2710087C (en) 2015-06-02
US20150342972A1 (en) 2015-12-03
KR101639772B1 (ko) 2016-07-15
MY148651A (en) 2013-05-15
UA119963C2 (uk) 2019-09-10
US9750759B2 (en) 2017-09-05
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
EP2231590B9 (en) 2012-08-15
DK2231633T3 (da) 2014-01-20
HRP20140015T1 (hr) 2014-02-14
CA2715203C (en) 2015-09-08
BRPI0821114A2 (pt) 2015-06-16
EP2597091B1 (en) 2016-04-20
AU2008341671A1 (en) 2009-07-02
ATE549313T1 (de) 2012-03-15
KR20100125226A (ko) 2010-11-30
ES2578606T3 (es) 2016-07-28
EP2231590A1 (en) 2010-09-29
PL2231590T3 (pl) 2012-09-28
US20110034549A1 (en) 2011-02-10
ZA201004017B (en) 2011-12-28
RU2010130253A (ru) 2012-01-27
NZ586013A (en) 2012-02-24
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
CY1117245T1 (el) 2017-04-05
CA2715203A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
GEP201706703B (en) Boronate ester compounds and pharmaceutical compositions thereof
ECSP099044A (es) Compuestos de pirimido fusionados
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
EA201170832A1 (ru) Пуриновые соединения
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
GEP20125702B (en) Benzimidazole derivatives
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BRPI0821116B8 (pt) composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2644, QUANTO AO NOME DE INVENTOR

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2806 DE 15-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.